Net income (loss) [USD, millions]

Depreciation and amortization [USD, millions]

Net accretion of bond discounts/premiums [USD, millions]

Loss on sale of marketable securities [USD, millions]

Amortization of right-of-use assets [USD, millions]

Amortization of collaboration contract asset [USD, millions]

Net loss on disposal of property, equipment and leasehold improvements [USD, millions]

Stock-based compensation [USD, millions]

Changes in operating assets and liabilities: Accounts receivable [USD, millions]

Changes in operating assets and liabilities: Other receivables [USD, millions]

Changes in operating assets and liabilities: Prepaid expenses and other assets [USD, millions]

Changes in operating assets and liabilities: Collaboration contract asset [USD, millions]

Changes in operating assets and liabilities: Accounts payable and accrued liabilities [USD, millions]

Changes in operating assets and liabilities: Operating lease liability [USD, millions]

Changes in operating assets and liabilities: Deferred revenue [USD, millions]

Net cash used in operating activities [USD, millions]

Purchases of marketable securities [USD, millions]

Maturities of marketable securities [USD, millions]

Sales of marketable securities [USD, millions]

Purchases of property, equipment and leasehold improvements [USD, millions]

Proceeds from disposal of property, equipment and leasehold improvements [USD, millions]

Net cash provided by (used in) investing activities [USD, millions]

Repayments of long-term debt [USD, millions]

Proceeds from issuance of common stock and pre-funded warrants [USD, millions]

Payment of common stock offering costs [USD, millions]

Proceeds from issuance of common stock [USD, millions]

Proceeds from exercise of stock options and issuance of ESPP shares [USD, millions]

Net cash provided by (used in) financing activities [USD, millions]

Net increase (decrease) in cash, cash equivalents and restricted cash [USD, millions]

Supplemental disclosure: Cash paid for taxes [USD, millions]

Cash, cash equivalents and restricted cash, beginning of period [USD, millions]

Cash, cash equivalents and restricted cash, end of period [USD, millions]

Supplemental disclosure: Purchases of property, equipment and leasehold improvements unpaid at period end [USD, millions]

f32f05cd4da94078843b3f3daffb984f3b6aa1ae3929fa63bb22a77c81195a83

Revenue (USD, millions)

Research and development expense (USD, millions)

General and administrative expense (USD, millions)

Total operating expenses (USD, millions)

Income (loss) from operations (USD, millions)

Other (expense) income, net (USD, millions)

Interest income, net (USD, millions)

Total other income (expense) (USD, millions)

Net income (loss) before income taxes (USD, millions)

Net loss before income taxes and loss from equity method investment (USD, millions)

Income tax expense (benefit) (USD, millions)

Loss from equity method investment (USD, millions)

Net income (loss) (USD, millions)

Earnings (loss) per common share - Basic (USD)

Earnings (loss) per common share - Diluted (USD)

Net loss per common share - basic and diluted (USD)

Weighted average common shares outstanding - Basic (millions)

Weighted average common shares outstanding - Diluted (millions)

Weighted average common shares outstanding - basic and diluted (millions)

Unrealized gain (loss) on available-for-sale securities (USD, millions)

Comprehensive income (loss) (USD, millions)

c4b9ecfcd18e03b419c4d31598fbe068d9464d09666ecefd7986761b1c297580

Cash and cash equivalents (USD, millions)

Restricted cash (USD, millions)

Marketable securities (USD, millions)

Accounts receivable (USD, millions)

Other receivables (USD, millions)

Prepaid expenses and other current assets (USD, millions)

Total current assets (USD, millions)

Property, equipment and leasehold improvements, net (USD, millions)

Operating lease right-of-use assets (USD, millions)

Collaboration contract asset and other assets (USD, millions)

Total assets (USD, millions)

Accounts payable and accrued liabilities (USD, millions)

Deferred revenue, current (USD, millions)

Current portion of operating lease liabilities (USD, millions)

Total current liabilities (USD, millions)

Deferred revenue, non-current (USD, millions)

Long-term debt (USD, millions)

Operating lease liabilities, non-current (USD, millions)

Total liabilities (USD, millions)

Preferred stock, $0.001 par value (USD, millions)

Common stock, $0.001 par value (Shares in millions)

Common stock, $0.001 par value (USD, millions)

Accumulated deficit (USD, millions)

Additional paid-in capital (USD, millions)

Accumulated other comprehensive income (loss) (USD, millions)

Total stockholders' equity (USD, millions)

Total liabilities and stockholders' equity (USD, millions)

2c11889f4d75f71534b284346fcdb80a12d8f85614cf22b50ab42f9d3cbe9d2c

Novartis License Agreement

Vepdegestrant Collaboration

Bayer Collaboration

Pfizer Research Collaboration

Oerth Bio Joint Venture

Restated Genentech Agreement

Luxdegalutamide

ARV-102

Bavdegalutamide

ARV-393

Other Programs

Total Revenue

85c648d290a92aa5aef8f8fee1ac7744505eb4ed7f92550ed31de790ce21dcc8

Number of patients for Phase 3 VERITAC-2 trial (patients)

Number of countries for Phase 3 VERITAC-2 trial (countries)

Number of participants for ARV-102 Phase 1 single ascending dose cohort (volunteers)

Number of treated individuals in ARV-102 Phase 1 single ascending dose cohort (individuals)

Number of placebo individuals in ARV-102 Phase 1 single ascending dose cohort (individuals)

Incidence rate of headaches in ARV-102 Phase 1 single ascending dose cohort – treated group (percent)

Incidence rate of headaches in ARV-102 Phase 1 single ascending dose cohort – placebo group (percent)

Incidence rate of fatigue in ARV-102 Phase 1 single ascending dose cohort – treated group (percent)

Incidence rate of fatigue in ARV-102 Phase 1 single ascending dose cohort – placebo group (percent)

Tumor regression rate for ARV-393 plus R-CHOP in preclinical DLBCL model (percent)

Tumor regression rate for ARV-393 plus small molecule inhibitors in preclinical DLBCL model (percent)

LRRK2 reduction in PBMC at single doses >=60 mg or repeated doses >=20 mg for ARV-102 (percent)

Reduction in phospho-Rab10T73 at single doses >=30 mg for ARV-102 (percent)

Reduction in bis(monoacylglycerol)phosphate in urine at single doses >=30 mg for ARV-102 (percent)

d9400620f88830705073b82f09bfdaa21fca4fd9ffc5eebbb3c99ee2a3cc5949

Arvinas Inc (ARVN)

Financials